CBC is another lesser-known yet still crucial cannabinoid in marijuana, especially from a therapeutic perspective. While bereft of the psychoactive quality of THC (and to a lesser extent THCV), CBC is gaining popularity as an anxiety reducer. While research on cannabichromene lags behind others, there’s good reason to continue looking into its potential as a medicine.
Until 2017, products containing cannabidiol marketed for medical purposes were classed as medicines by the UK regulatory body, the Medicines and Healthcare products Regulatory Agency (MHRA) and could not be marketed without regulatory approval for the medical claims. As of 2018, cannabis oil is legal to possess, buy, and sell in the UK, providing the product does not contain more than 0.2% THC and is not advertised as providing a medicinal benefit.
All CBD products start out the same way: as an extract from the leaves and flowers of cannabis plants. At Green Roads, we only extract CBD from hemp, defined as any variety of cannabis plant containing less than 0.3% THC by dry weight. Cannabinoids and terpenes are produced by tiny glands on the leaves and flowers of cannabis plants known as trichomes. The compounds produced by these trichomes give cannabis both its rich aroma and its nutraceutical effects.
Born in the foothills of the Rocky Mountains, we’ve been growing some of the safest and most thoroughly tested medical cannabis on the market since 2016. Our state-of-the-art facility in Cremona, Alberta, was specifically designed to keep our plants happy, and alongside a meticulous process of harvesting and curing we ensure only the best product arrives at your door.
It is not surprising that male-associated markers are relatively abundant. In dioecious plants where sex chromosomes have not been identified, markers for maleness indicate either the presence of sex chromosomes which have not been distinguished by cytological methods or that the marker is tightly linked to a gene involved in sex determination.
According to the United States Department of Health and Human Services, there were 455,000 emergency room visits associated with cannabis use in 2011. These statistics include visits in which the patient was treated for a condition induced by or related to recent cannabis use. The drug use must be "implicated" in the emergency department visit, but does not need to be the direct cause of the visit. Most of the illicit drug emergency room visits involved multiple drugs. In 129,000 cases, cannabis was the only implicated drug.
Cooper recently got funding from the National Institutes of Health for a study looking at cannabinoids — including CBD in isolation — as a substitute for opioids, and numerous other clinical trials of CBD are underway. It will be several years before results are available, but these studies should help clarify both what benefits the substance may provide and any side effects it may come with. Most of the adverse effects so far associated with cannabis, such as impairments in short-term memory, coordination and judgment,2 come from products that contain THC as well as CBD, Cooper said, but we need to do more studies to find out for sure whether CBD has fewer risks. Studies are also needed to identify the best way to administer and dose CBD. “I get emails from people asking me what dose of CBD to use, and the truth is, we really don’t know,” Cooper said.
^ Juliet Eilperin (February 11, 2013), "'Good seed' versus 'evil weed': Hemp activists eye legalization", The Washington Post – via The Japan Times Online, [A] couple of factors — the high taxes the federal government imposed on growing hemp in the late 1930s and again in the early '50s, and then the DEA's interpretation of the 1970 law — made producing hemp nearly impossible. Since the DEA only grants permits in rare instances and demands costly, elaborate security precautions, large-scale hemp growing in the United States is not viable.